INSTITUT PASTEUR

Sensorion reported positive initial safety data for Audiogene, its Phase 1/2 gene therapy trial of SENS-501, and final results of the Phase 2a trial of SENS-401 after cochlear implantation. Preliminary safety and efficacy data were also reported for the NOTOXIS trial, a Phase 2a study of SENS-401 in preventing Cisplatin-Induced Ototoxicity. The company aims to advance innovative programs to transform the quality of hearing for patients with hearing disorders.

Sensorion reports first patient treated in SENS-501 Audiogene study, on-track for first cohort recruitment by year-end 2024. Final data from SENS-401 Phase 2a study in cochlear implantation preservation to be presented at WCA on September 20, 2024. Preliminary efficacy and safety data of SENS-401 Phase 2a in Cisplatin-Induced Ototoxicity also to be presented at WCA. Cash on-hand of €87m supports operations into end of 2025.